Home
HelpTest ID: LMPP Lipoprotein Metabolism Profile, Serum
Reporting Name
Lipoprotein Metabolism ProfileUseful For
Diagnosing dyslipoproteinemia
Quantifying cholesterol and triglycerides in very-low-density lipoprotein, low-density lipoprotein (LDL), high-density lipoproteins (HDL), and chylomicrons
Identifying lipoprotein-X
Classifying hyperlipoproteinemias (lipoprotein phenotyping)
Evaluating patients with abnormal lipid values (cholesterol, triglyceride, HDL, LDL) for specific phenotypes
Clinical Information
Lipoprotein metabolism profile analysis adds practical information about the etiology of cholesterol and/or triglyceride elevation. In some patients, increased serum lipids reflect elevated levels of intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein a (Lp[a]), or even the abnormal lipoprotein complex, LpX. These elevations can be indicative of a genetic deficiency in lipid metabolism or transport, nephrotic syndrome, endocrine dysfunction, or even cholestasis. Identification of the lipoprotein associated with lipid elevation is achieved using the gold-standard methods, which include ultracentrifugation, selective precipitation, electrophoresis, and direct measurement of cholesterol and triglycerides in isolated lipoprotein fractions. Proper characterization of a patient's dyslipidemic phenotype aids clinical decisions and guides appropriate therapy.
Classifying the hyperlipoproteinemias into phenotypes places disorders that affect plasma lipid and lipoprotein concentrations into convenient groups for evaluation and treatment. A clear distinction must be made between primary (inherited) and secondary (liver disease, alcoholism, metabolic diseases) causes of dyslipoproteinemia. Lipoprotein profiling will identify the presence of Lp(a) and LpX and distinguish between the following dyslipidemias:
-Exogenous hyperlipemia (Type I)
-Familial hypercholesterolemia (Type IIa)
-Familial combined hyperlipidemia (Type IIb)
-Familial dysbetalipoproteinemia (Type III)
-Endogenous hyperlipemia (Type IV)
-Mixed hyperlipemia (Type V)
Interpretation
Patients with increased lipoprotein a (Lp[a]) cholesterol values have been associated with increased risk for the development of atherothrombotic disease. Aggressive low-density lipoprotein reduction is the recommended treatment approach in most patients with increased Lp(a).
Lipoprotein-X (LpX) is an abnormal lipoprotein that appears in the sera of patients with obstructive jaundice and is an indicator of cholestasis. The presence of LpX will be reported if noted during Lp(a) cholesterol analysis.
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| TCS | Cholesterol, Total, CDC, S | No | Yes |
| TRIGC | Triglycerides, CDC, S | No | Yes |
| APLBS | Apolipoprotein B, S | Yes, (order APOLB) | Yes |
| HDLS | HDL Cholesterol, CDC, S | No | Yes |
| LMPP1 | Lipoprotein Metabolism Profile 1 | No | Yes |
Report Available
2 to 4 daysDay(s) Performed
Monday through Thursday, Sunday
Clinical Reference
1. Grundy SM, Stone NJ, Bailey AL, et al: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143
2. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute: Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011 Dec;128 Suppl 5:S213-S256
3. Rosenson RS, Najera SD, Hegele RA: Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome. J Clin Lipidol. 2017 Jan-Feb;11(1):294-296. doi: 10.1016/j.jacl.2016.12.005
4. Hopkins PN, Brinton EA, Nanjee MN: Hyperlipoproteinemia type 3: the forgotten phenotype. Curr Atheroscler Rep. 2014 Sep;16(9):440. doi: 10.1007/s11883-014-0440-2
5. Gotoda T, Shirai K, Ohta T, et al: Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012;19(1):1-12
6. Gonzales KM, Donato LJ, Shah P, Simha V: Measurement of apolipoprotein B levels helps in the identification of patients at risk for hypertriglyceridemic pancreatitis. J Clin Lipidol. 2021 Jan-Feb;15(1):97-103. doi: 10.1016/j.jacl.2020.11.010
7. Fatica EM, Meeusen JW, Vasile VC, Jaffe AS, Donato LJ: Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. Clin Biochem. 2020 Dec;86:45-51. doi: 10.1016/j.clinbiochem.2020.09.007
8. Arnett DK, Blumenthal RS, Albert MA, et al: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646
Method Name
TCS, TRIGD: Enzymatic Colorimetric
APLBS: Automated Turbidimetric Immunoassay
HDLS: Selective Precipitation, Enzymatic Colorimetric
LMPP1: Ultracentrifugation/Electrophoresis/Automated Enzymatic/Colorimetric Analysis
Specimen Type
SerumNecessary Information
Patient's age and sex are required.
Specimen Required
Patient Preparation:
1. Fasting-overnight (12-14 hours)
2. Patient must not consume any alcohol for 24 hours before the specimen is collected.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 7 days | |
| Frozen | 60 days |
Reference Values
|
2-9 years |
10-17 years |
≥18 years |
|
|
Total cholesterol |
* Acceptable: <170 mg/dL Borderline high: 170-199 mg/dL High: ≥200 mg/dL |
** Desirable: <200 mg/dL Borderline high: 200-239 mg/dL High: ≥ 240 mg/dL |
|
|
Triglycerides |
* Acceptable: <75 mg/dL Borderline high: 75-99 mg/dL High: ≥100 mg/dL |
* Acceptable: <90 mg/dL Borderline high: 90-129 mg/dL High: ≥130 mg/dL |
** Normal: <150 mg/dL Borderline high: 150-199 mg/dL High: 200-499 mg/dL Very high: ≥500 mg/dL |
|
Low-density lipoprotein (LDL) cholesterol |
* Acceptable: <110 mg/dL Borderline high: 110-129 mg/dL High: ≥130 mg/dL |
*** Desirable: <100 mg/dL Above Desirable: 100-129 mg/dL Borderline high: 130-159 mg/dL High: 160-189 mg/dL Very high: ≥190 mg/dL |
|
|
LDL triglycerides |
≤50 mg/dL |
≤50 mg/dL |
|
|
Apolipoprotein B |
* Acceptable: <90 mg/dL Borderline high: 90-109 mg/dL High: ≥110 mg/dL |
*** Desirable: <90 mg/dL Above Desirable: 90-99mg/dL Borderline high: 100-119 mg/dL High: 120-139 mg/dL Very high: ≥140 mg/dL |
|
|
High-density lipoprotein (HDL) cholesterol |
* Low: <40 mg/dL Borderline low: 40-45 mg/dL Acceptable: >45 mg/dL |
*** Males: ≥40mg/dL Females: ≥50mg/dL |
|
|
Very low-density lipoprotein (VLDL) cholesterol |
<30 mg/dL |
<30 mg/dL |
|
|
VLDL triglycerides |
<90 mg/dL |
<120 mg/dL |
|
|
Beta VLDL cholesterol |
<15 mg/dL |
<15 mg/dL |
|
|
Beta VLDL triglycerides |
<15 mg/dL |
<15 mg/dL |
|
|
Chylomicron cholesterol |
Undetectable |
Undetectable |
|
|
Chylomicron triglycerides |
Undetectable |
Undetectable |
|
|
Lp(a) cholesterol |
<5 mg/dL |
<5 mg/dL |
|
|
LpX |
Undetectable |
Undetectable |
|
Reference values have not been established for patients who are less than 2 years of age.
*Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents
**National Cholesterol Education Program (NCEP)
***National Lipid Association
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
80061-Lipid panel (includes: HDL [CPT Code 83718], total cholesterol [CPT Code 82465], and triglycerides [CPT Code 84478] if all performed)
82172-Apolipoprotein B
83700-Lp(a) cholesterol electrophoresis
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| LMPP | Lipoprotein Metabolism Profile | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| TCS | Cholesterol, Total, CDC, S | 2093-3 |
| HDLS | HDL Cholesterol, CDC, S | 2085-9 |
| TRIGC | Triglycerides, CDC, S | 2571-8 |
| APLBS | Apolipoprotein B, S | 1884-6 |
| 2839 | LDL Cholesterol | 2089-1 |
| 2840 | LDL Triglycerides | 3046-0 |
| 2844 | VLDL cholesterol | 2091-7 |
| 2847 | VLDL triglycerides | 3047-8 |
| 2842 | Beta VLDL Cholesterol | 66499-5 |
| 2843 | Beta VLDL triglycerides | 3045-2 |
| 2855 | Chylomicron cholesterol | 34467-1 |
| 2856 | Chylomicron triglycerides | 35363-1 |
| 2849 | Lp(a) Cholesterol | 35388-8 |
| 23924 | LpX | 42178-4 |
| 23937 | Interpretation | 59462-2 |
Forms
If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.
mml-diabetes-metabolic-nutrition